Rosuvastatin is associated with increased risks for hematuria, proteinuria, and kidney failure with replacement therapy (KFRT) compared with atorvastatin use, according to a study published in the Journal of the American Society of Nephrology. Jung-Im Shin, MD, and colleagues used deidentified EHR data and analyzed 152,101 new users of rosuvastatin and 795,799 new users of atorvastatin during 2011-2019. During a median follow-up of 3.1 years, hematuria was observed in 2.9% of patients and proteinuria in 1.0%. Rosuvastatin use was associated with increased risks for hematuria, proteinuria, and KFRT compared with atorvastatin (HRs, 1.08, 1.17, and 1.15, respectively). Among patients with an estimated glomerular filtration rate of less than 30 mL/min/1.73 m2, 44% were prescribed high-dose rosuvastatin (20 or 40 mg daily) despite current labeling suggesting dosage reduction (maximum daily dose, 10 mg) for patients with severe chronic kidney disease.
